NASHVILLE, Tenn., Sept 08, 2010 /PRNewswire via COMTEX News Network/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the Stifel Nicolaus 2010 Healthcare Conference at the Four Seasons in Boston on Thursday, September 16, 2010, at 1:30 p.m. Eastern Time.
The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section of Cumberland Pharmaceuticals' website at www.cumberlandpharma.com. Shortly following the live webcast a replay will also be available on the Company's website.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning, Caldolor(R), the first injectable treatment for pain and fever approved in the United States, and Kristalose(R), a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information on Cumberland Pharmaceuticals, please visit the Company website at www.cumberlandpharma.com.
About Stifel Nicolaus Weisel
Stifel Financial Corp. is a full-service regional brokerage and investment banking firm established in 1890 and based in St. Louis. In July 2010, Stifel completed a merger with Thomas Weisel Partners Group, Inc., furthering Stifel's mission of building the premier middle-market investment bank with significantly enhanced investment banking, research and wealth management capabilities. The investment banking platform of Stifel, Nicolaus & Company now operates under the Stifel Nicolaus Weisel name. A leading investment bank focused on the middle-market, Stifel Nicolaus manages public offerings of equity and debt securities, raises debt and equity in private markets, and structures mergers, acquisitions and divestitures.
Contact: Angela Novak Investor Relations (615) 255-0068 firstname.lastname@example.org
SOURCE Cumberland Pharmaceuticals Inc.
Copyright (C) 2010 PR Newswire. All rights reserved